Analytical Validation of Variants to Aid in Genotype-Guided Therapy for Oncology

The Clinical Laboratory Improvement Amendments (CLIA) of 1988 requires that pharmacogenetic genotyping methods need to be established according to technical standards and laboratory practice guidelines before testing can be offered to patients. Testing methods for variants in ABCB1, CBR3, COMT, CYP3A7, C8ORF34, FCGR2A, FCGR3A, HAS3, NT5C2, NUDT15, SBF2, SEMA3C, SLC16A5, SLC28A3, SOD2, TLR4, and TPMT were validated in a CLIA-accredited laboratory. As no known reference materials were available, DNA samples that were from Coriell Cell Repositories (Camden, NJ) were used for the analytical validation studies.

Source: Journal of Molecular Diagnostics - February 20, 2019 Category: Pathology Authors: Marelize Swart, Wesley M. Stansberry, Victoria M. Pratt, Elizabeth B. Medeiros, Patrick J. Kiel, Fei Shen, Bryan P. Schneider, Todd C. Skaar Tags: Regular article Source Type: research